Skip to main content

For Accelrys, Bookings Up, but Revenues Down in FY 05 Q3

NEW YORK, Jan. 26 (GenomeWeb News) - Accelrys today reported an increase in orders for the third quarter of its 2005 fiscal year, but a decrease in quarterly revenues resulting from a change in its accounting practices.

 

Accelrys reported total bookings of $37.9 million for the quarter ended Dec. 31, 2004 -- an increase of 9-percent over $34.8 million booked for the same quarter of 2003. Revenues, however, which the company now recognizes on a ratable subscription basis, declined to $22.2 million -- a 30-percent drop from revenues of $31.6 million in the year-ago period.

 

In line with the change in the company's revenue recognition practice, deferred revenue increased during the quarter, from $29.5 million as of Sept. 30, 2004, to $43.4 million as of Dec. 31, 2004.

 

The company's quarterly expenses rose to $28.5 million, from $23.5 million in the prior-year period. Accelrys said that $3.3 million of these expenses were associated with its acquisition of SciTegic, which closed in September.

 

Accelrys spent $4.7 million on R&D during the quarter, a slight increase from $4.6 million in the prior year.

 

The company posted a quarterly net loss of $5.7 million, compared to $7.9 million in net income that it reported for the comparable period of 2003.

 

Accelrys held $59.1 million in cash, cash equivalents, restricted cash, and marketable securities as of Dec. 31, 2004.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.